Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8606121 | 0.81 | HDAC6 (0.34) | HDAC6HDAC1HDAC2ELANEDGAT1 | |
| SCHEMBL27573874 | 0.79 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL12519845 | 0.79 | HDAC6 (0.38) | HDAC6HDAC1HDAC2ELANEDGAT1 | |
| SCHEMBL4855501 | 0.78 | HDAC6 (0.36) | HDAC6HDAC1HDAC2ELANEDGAT1 | |
| SCHEMBL6754575 | 0.77 | HDAC6 (0.37) | HDAC6HDAC1HDAC2ELANEDGAT1 | |
| SCHEMBL187396 | 0.77 | ALDH1A1 (0.60) | HDAC6HDAC1HDAC2ELANEDGAT1 | |
| SCHEMBL2597430 | 0.77 | HDAC6 (0.37) | HDAC6HDAC1HDAC2ELANEDGAT1 | |
| SCHEMBL3134646 | 0.76 | HDAC6 (0.34) | HDAC6HDAC1HDAC2ELANEDGAT1 | |
| SCHEMBL4393654 | 0.75 | HDAC6 (0.40) | HDAC6HDAC1HDAC2ELANEDGAT1 | |
| SCHEMBL697016 | 0.75 | HTT (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3313851-A1 | NEW HYDROXYESTER DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Les Laboratoires Servier (FR) | 2018-05-02 | — | — | EP | claimed |
| WO-2016207225-A1 | NEW HYDROXYESTER DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2016-12-29 | — | — | WO | claimed |
| US-7378548-B2 | Tertiary amine compounds having an ester structure and processes for preparing the same | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2008-05-27 | — | — | US | claimed |
| US-20060217570-A1 | Novel Tertiary Amine Compounds Having An Ester Structure And Processes For Preparing The Same | SHIN-ETSU CHEMICAL CO., LTD. | 2006-09-28 | — | — | US | claimed |
| CN-1185211-C | Benzamide derivatives for the treatment of diseases caused by cytokines | ASTRA ZENECA LTD (SE) | 2005-01-19 | — | — | CN | claimed |
| CN-1300278-A | Benzamide derivatives for the treatment of diseases caused by cytokines | ASTRA ZENECA LTD (SE) | 2001-06-20 | — | — | CN | claimed |
| EP-0730590-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-09-11 | — | — | EP | claimed |
| EP-0370454-B1 | Renin-inhibiting amino diol derivatives | HOECHST AG (DE) | 1994-04-20 | — | — | EP | claimed |
| US-5073551-A | Antibiotics | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1991-12-17 | — | — | US | claimed |
| EP-0370454-A2 | Renin-inhibiting amino diol derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-05-30 | — | — | EP | claimed |
| EP-0335390-A2 | Novel cephalosporin compounds | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1989-10-04 | — | — | EP | claimed |
| EP-0329013-A2 | Renin-inhibiting amino acid derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-08-23 | — | — | EP | claimed |
| US-4376770-A | OXACEPHALOSPORINS | SHIONOGI & CO., LTD. (JP) | 1983-03-15 | — | — | US | claimed |
| CN-118109069-A | Resin composition, cured product, and method for producing cured product | 东京应化工业株式会社 | 2024-05-31 | — | — | CN | disclosed |
| CN-118108899-A | Curable resin composition, cured product, and method for producing cured product | 东京应化工业株式会社 | 2024-05-31 | — | — | CN | disclosed |
| EP-2686296-B1 | SUBSTITUTED 4-CYAN-3-(2,6-DIFLUOROPHENYL)-4-PHENYLBUTANOATES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS HERBICIDES AND PLANT GROWTH REGULATORS | BAYER CROPSCIENCE AG (DE) | 2018-09-26 | — | — | EP | disclosed |
| US-4731362-A | Alkylcarbamoyloxymethylcephem compounds | SHIONOGI & CO., LTD. (JP) | 1988-03-15 | — | — | US | disclosed |
| EP-0215355-A2 | Erythromycin derivative and process for preparing the same | KITASATO KENKYUSHO (JP) | 1987-03-25 | — | — | EP | disclosed |
| EP-0213617-A2 | Digestive tract contractile motion stimulant | KITASATO KENKYUSHO (JP) | 1987-03-11 | — | — | EP | disclosed |
| US-4496562-A | 7-Substituted-3-cephem-4-carboxylic acid esters | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217570-A1 | Novel Tertiary Amine Compounds Having An Ester Structure And Processes For Preparing The Same | HRH3, HRH4, HRH2 | HDAC6 3643/4885HDAC1 2476/4885HDAC2 2351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.